心臟组织工程市场：按产品类型、技术、细胞来源、应用和最终用户划分－2026-2032年全球预测

预计到 2025 年，心臟组织工程市场价值将达到 113.2 亿美元，到 2026 年将成长至 122.7 亿美元，到 2032 年将达到 205.7 亿美元，复合年增长率为 8.89%。

主要市场统计数据
基准年 2025	113.2亿美元
预计年份：2026年	122.7亿美元
预测年份 2032	205.7亿美元
复合年增长率 (%)	8.89%

对心臟组织工程的进展、临床需求和转化研究重点进行简洁的基础性概述，这些进展将影响短期发展。

心臟组织工程已从以学术研究为主转向以临床为导向的领域，这主要源于心血管疾病治疗中亟待满足的需求以及替代疗法的局限性日益凸显。过去十年间，生物材料、干细胞生物学和製造技术的进步汇聚一堂，催生出旨在恢復心肌功能、重组瓣膜和设计血管移植物等实用化方法。因此，产业界、学术界和临床实践中的相关人员越来越关注实用化里程碑，而非纯粹的探索性研究目标。

基础技术、製造系统和监管变革的重组，正在共同重新定义心臟组织工程的商业化路径。

心臟组织工程领域正经历着一场变革性的转变，这场转变由三个相互依存的动态驱动：基础技术的成熟、供应炼和製造模式的重组，以及强调品质和扩充性的监管要求的演变。首先，精密製造技术和细胞工程技术正从概念验证阶段发展成为可控且可扩展的工艺，从而支持临床应用。这些技术进步包括高度复杂的生物材料化学、能够实现功能整合的模组化支架设计，以及能够降低免疫抗原性风险并提高移植成功率的细胞筹资策略。

2025年关税调整对心臟组织工程采购、供应链韧性和策略性在地化的实际影响

2025年的政策环境引入了新的关税趋势，对心臟组织工程价值链中的全球采购、零件成本结构和在地化策略产生了切实的影响。影响进口特殊材料、某些医疗设备子组件以及部分生物製药相关耗材的关税措施，增加了跨境采购的成本和复杂性。为此，各组织正在审查供应商合约和库存策略，以降低贸易相关成本不可预测成长带来的风险。

我们对产品、技术、电池来源、应用领域和最终用户进行综合細項分析，以明确商业性和实用化优先事项。

从多维度的市场区隔观点来理解市场，有助于明确科学创新与商业性机会的交会点。产品差异化至关重要：生物人工心臟包括用于恢復特定心室功能的部分心臟和旨在实现全器官替代的全心臟。心臟贴片包括由天然细胞外基质建构的去细胞贴片和利用工程化纤维结构的静电纺丝贴片。心臟支架的选择范围很广，既有利用内源性讯号传导的生物来源支架，也有具有精确工程化机械性质和降解特性的合成支架。注射型水凝胶进一步分为促进细胞介导重塑的天然水凝胶和具有可调控制释放和机械增强功能的合成水凝胶。这些产品特性决定了生产流程、监管合规策略和临床应用方案。

美洲、欧洲、中东和非洲以及亚太地区的区域战略存在差异和机会，这些差异和机会会影响发展、製造和市场进入。

科学生态系统、报销政策和生产基础设施的地域差异造就了独特的策略机会和限制因素。在美洲，健全的临床试验网络、先进的医院系统和活跃的创投界正在加速平台技术向早期人体试验的转化，同时也在促进区域生产能力的建立，以满足监管机构和支付方的期望。相较之下，欧洲、中东和非洲地区的法规结构各不相同，生产成熟度也存在差异。该地区通常作为创新报销模式和公私合营倡议的试验场，旨在降低国家或超国家层面的临床应用风险。

多元化的公司结构、合作关係和商业化活动如何塑造竞争动态和策略整合。

心臟组织工程领域的企业活动日益多元化，各类公司在生态系中扮演互补的角色。领先的生物技术公司和专业医疗设备开发商正在推动平台技术的发展并建立临床路径，而大型製药企业和成熟的医疗设备製造商则有选择地寻求合作伙伴关係和产能收购，以进入再生医学心血管解决方案市场。合约开发和生产组织（CDMO）正在成为团队扩大生产规模并减轻自身基础设施资本负担的关键支援机构，而学术衍生公司则继续提供早期创新和专业知识，以支持转化研发管线。

为产业领导者提供可操作的策略重点，以协调技术开发、製造、监管策略和伙伴关係模式，从而实现临床成功。

产业领导者应采取兼顾技术雄心与实际营运执行的策略，以加速临床应用和商业性化进程。首先，他们应优先考虑平台稳健性，从研发早期阶段就投资于可製造性。建立扩充性且可重复的流程能够降低后期风险，并提升对策略伙伴和买家的吸引力。其次，他们应推行模组化产品策略，实现分阶段进入临床，同时保留拓展适应症和平台演进的潜力。这种方法使企业能够在目标应用场景中儘早获得临床证据，并根据实际应用效果不断迭代改进。

采用稳健的混合方法研究方法，结合专家的初步访谈、文献和专利分析、监管审查以及使用三角测量法的二手资料检验。

本调查方法结合了迭代式的一手研究和全面的二手调查，旨在多角度了解心臟组织工程的现况。一手研究包括对来自生技和医疗设备公司的各类相关人员进行深入访谈，其中包括高阶主管、生产经理、临床研究人员以及监管和报销专家。研究收集了有关策略重点、营运限制和循证计划的定性见解，并将其纳入分析框架。

临床、营运和策略需求的整合决定了哪些心臟组织工程创新能够产生持久的临床和商业性影响。

心臟组织工程正处于关键的转折点，技术成熟度、商业性意图和监管现实在此交汇，有望产生意义深远的临床影响。未来的发展取决于研发人员能否将平台创新转化为可生产、安全有效且符合临床医生、监管机构和支付方期望的治疗方法。策略性地聚焦于可扩展的生产、多元化的采购管道以及早期与监管机构的沟通，对于将科学潜力转化为可持续的临床解决方案至关重要。

目录

第一章：序言

第二章：调查方法

• 调查设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查的前提
• 研究限制

第三章执行摘要

• 首席主管观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会映射
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 心臟组织工程市场：依产品类型划分

• 生物人工心臟
  • 部分心臟
  • 全心全意
• 心形补丁
  • 脱细胞贴片
  • Electrospan 贴片
• 心臟支架
  • 生物支架
  • 合成支架
• 可注射水凝胶
  • 天然水凝胶
  • 合成水凝胶

第九章 心臟组织工程市场：依技术划分

• 3D生物列印
  • 挤出式
  • 喷墨法
  • 雷射辅助型
• 去细胞基质
  • 组织段脱细胞
  • 整个器官的去细胞化
• 干细胞疗法
  • 胚胎干细胞
  • 诱导性多功能干细胞
  • 间质干细胞

第十章：以细胞来源分類的心臟组织工程市场

• 同种异体移植
  • 供体心肌细胞
  • 供体基质细胞
• 自有住房
  • 心肌细胞
  • 基质细胞
• 异种移植
  • 牛源细胞
  • 猪源细胞

第十一章 心臟组织工程市场：依应用领域划分

• 心臟瓣膜再生
  • 生物瓣膜再生
  • 机械阀更换
• 心肌修復
  • 修復先天性缺陷
  • 心肌梗塞后的修復
• 血管移植
  • 冠状动脉绕道手术
  • 週边血管修復

第十二章 心臟组织工程市场：依最终使用者划分

• 生技公司
• 医院
• 製药公司
• 研究机构

第十三章 心臟组织工程市场：依地区划分

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 心臟组织工程市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 心臟组织工程市场：依国家划分

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章：美国心臟组织工程市场

第十七章：中国心臟组织工程市场

第十八章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Artivion, Inc.
• Auto Tissue Berlin GmbH
• Avery Therapeutics, Inc.
• Baxter Internatioal Inc.
• BICO Group AB
• Boston Scientific Corporation
• BPS Bioscience, Inc.
• Elutia Inc.
• Fujifilm Holdings Corporation
• Matricelf, Inc.
• Medtronic Plc
• Merck KGaA
• Meril Lifesciences Pvt. Ltd.
• Ncardia BV
• Organovo Holdings, Inc.
• PromoCell GmbH
• Teijin Limited
• Terumo Corporation
• Vascudyne, Inc.
• Viscofan DE GmbH

The Cardiac Tissue Engineering Market was valued at USD 11.32 billion in 2025 and is projected to grow to USD 12.27 billion in 2026, with a CAGR of 8.89%, reaching USD 20.57 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 11.32 billion
Estimated Year [2026]	USD 12.27 billion
Forecast Year [2032]	USD 20.57 billion
CAGR (%)	8.89%

Concise foundational overview of cardiac tissue engineering advances, clinical imperatives, and translational priorities shaping near-term development

Cardiac tissue engineering has moved from a predominantly academic pursuit to a clinically focused discipline driven by urgent unmet needs in cardiovascular disease management and the increasing limitations of replacement therapies. Over the past decade, advances in biomaterials, stem cell biology, and fabrication technologies have converged to create translationally viable approaches aimed at restoring myocardial function, reconstructing valves, and engineering vascular conduits. As a result, stakeholders across industry, academia, and clinical practice are increasingly aligning around translational milestones rather than purely exploratory research objectives.

Translational progress has been accompanied by more rigorous regulatory engagement and a growing number of early human feasibility studies that emphasize safety, reproducibility, and durability. At the same time, investment patterns and strategic partnerships have begun to reflect an appetite for de-risked, platform-based solutions that can be adapted across indications. This evolution requires that decision-makers balance near-term clinical demands against the long-tail development timelines intrinsic to regenerative strategies, while also accounting for manufacturing, supply chain, and reimbursement realities that will determine long-term adoption.

How enabling technologies, manufacturing realignment, and regulatory evolution are jointly redefining commercial pathways in cardiac tissue engineering

The landscape of cardiac tissue engineering is undergoing transformative shifts driven by three interdependent dynamics: the maturation of enabling technologies, realignment of supply chains and manufacturing paradigms, and evolving regulatory expectations that foreground quality and scalability. First, precision fabrication methods and cellular engineering techniques are moving beyond proof-of-concept toward controlled, scalable processes that support clinical translation. These technological advances include increasingly refined biomaterial chemistries, modular scaffold designs that permit functional integration, and cellular sourcing strategies that reduce immunogenic risk and enhance engraftment potential.

Second, commercialization pathways are being recalibrated as industry participants pursue vertically integrated manufacturing or strategic partnerships with specialized contract development and manufacturing organizations. This shift is motivated by the need to ensure consistent product quality, traceability, and cost-effective scale-up. Third, regulatory agencies are signaling a pragmatic approach that balances expedited access for high-need indications with robust post-market surveillance and real-world evidence requirements. Consequently, developers are prioritizing product dossiers that demonstrate not only efficacy but also process control, sterility assurance, and long-term safety monitoring. Together, these shifts compress the gap between laboratory innovation and clinical application while raising the bar for operational excellence and stakeholder alignment.

Practical repercussions of 2025 tariff shifts on sourcing, supply chain resilience, and strategic localization in cardiac tissue engineering

The policy environment in 2025 introduced new tariff dynamics that have tangible implications for global sourcing, component cost structures, and localization strategies within the cardiac tissue engineering value chain. Tariff measures affecting imported specialty materials, certain medical device subcomponents, and, in some cases, biologics-adjacent supplies have increased the cost and complexity of cross-border procurement. In response, organizations are reassessing supplier contracts and inventory strategies to mitigate exposure to unpredictable trade-related cost increases.

Consequently, many developers and suppliers are accelerating the localization of critical inputs and onshore manufacturing capabilities to maintain tighter control over quality and supply continuity. This trend is amplifying interest in regional manufacturing hubs, which help reduce lead times and logistical risk but require upfront capital and regulatory alignment. Additionally, increased tariff pressure is encouraging closer collaboration between upstream material innovators and downstream device developers to redesign products that rely on locally sourced or tariff-exempt materials without compromising biocompatibility or performance.

At an operational level, procurement and commercial teams are placing greater emphasis on supplier diversification, multi-sourcing strategies, and risk-adjusted contract clauses that account for trade policy volatility. Meanwhile, investors and corporate strategists are evaluating the trade-offs between higher near-term capital expenditures for localized capacity versus longer-term resilience and reduced exposure to tariff-driven cost shocks. These strategic adjustments are reshaping cost models, partnership architectures, and the timelines by which emerging therapies can be competitively manufactured and distributed.

Integrated segmentation analysis aligning products, technologies, cell sources, applications, and end users to illuminate commercial and translational priorities

Understanding the market through a multifaceted segmentation lens offers clarity on where scientific innovation meets commercial opportunity. Product differentiation is meaningful: bioartificial hearts encompass both partial hearts designed to restore specific chamber function and whole hearts that pursue organ-scale replacement; cardiac patches include decellularized patches built from native extracellular matrices and electrospun patches that leverage engineered fiber architectures; cardiac scaffolds present options between biological scaffolds that capitalize on endogenous signaling and synthetic scaffolds engineered for precise mechanical and degradation profiles; and injectable hydrogels split into natural hydrogels that promote cell-mediated remodeling and synthetic hydrogels tailored for tunable release and mechanical reinforcement. These product distinctions inform manufacturing pathways, regulatory strategies, and clinical adoption scenarios.

Parallel to product segmentation, technology choices define developmental risk and scalability. Three-dimensional bioprinting encompasses extrusion based, inkjet based, and laser assisted approaches, each with specific implications for resolution, cell viability, and throughput. Decellularized matrices can be pursued at the tissue segment level for patch-like applications or at the whole organ scale for complex reconstructions, placing distinct demands on donor sourcing and sterilization processes. Stem cell therapy strategies vary between embryonic stem cells, induced pluripotent stem cells, and mesenchymal stem cells, with differences in differentiation potential, ethical considerations, and immunogenic profile. Cell source itself further refines strategic positioning: allogeneic models may leverage donor cardiomyocytes and donor stromal cells for off-the-shelf scalability, autologous approaches rely on patient-derived cardiomyocytes and stromal cells to minimize rejection risk, and xenogeneic options such as bovine and porcine cells introduce complex immunological and regulatory considerations.

Application-focused segmentation helps align clinical evidence and market access pathways. Heart valve regeneration spans biological valve regeneration strategies that aim to recreate living valve tissue and mechanical valve replacement alternatives that represent the incumbent approach; myocardial repair divides into congenital defect repair and post infarction repair, each with unique patient populations and endpoints; vascular grafting comprises coronary artery bypass solutions and peripheral vascular repair applications that differ in flow dynamics and device specifications. Finally, end user segmentation sheds light on commercial routes and procurement dynamics, where biotechnology companies drive innovation and productization, hospitals and pharmaceutical companies shape clinical adoption and distribution, and research institutes sustain early-stage discovery and translational validation. Integrating these segmentation perspectives enables clearer prioritization of development programs, partnership models, and evidence generation plans.

Regional strategic contrasts and opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence development, manufacturing, and market access

Geographic variation in scientific ecosystems, reimbursement policies, and manufacturing infrastructure creates distinct strategic opportunities and constraints. In the Americas, strong clinical trial networks, advanced hospital systems, and active venture and corporate investment communities are accelerating the translation of platform technologies into early human studies, while also encouraging the establishment of localized manufacturing capacity to meet regulatory and payer expectations. In contrast, Europe, Middle East & Africa exhibit heterogeneous regulatory frameworks and varied levels of manufacturing maturity; this region often serves as a testing ground for innovative reimbursement models and collaborative public-private initiatives that can de-risk clinical translation at the national or supra-national level.

Asia-Pacific is characterized by rapidly expanding clinical research capacity, significant government-led investments in biotech infrastructure, and an increasing number of domestic developers pursuing both regional and global market entry. Each region presents different opportunities for strategic partnerships: localized supply chains in the Americas can support rapid commercialization for high-value indications, regulatory harmonization efforts in Europe, Middle East & Africa can facilitate multi-country rollouts of standardized products, and scaling opportunities in Asia-Pacific can help developers access large patient populations and specialized manufacturing talent. A regionalized approach to product development and commercialization - one that respects local regulatory expectations, clinical practice patterns, and procurement dynamics - will be essential for companies seeking durable presence across these diverse markets.

How diverse company archetypes, partnership modalities, and commercialization behaviors are shaping competitive dynamics and strategic consolidation

Company activity in cardiac tissue engineering is increasingly distributed across several archetypes that play complementary roles in the ecosystem. Leading biotechnology players and specialized device developers are advancing platform technologies and establishing clinical pathways, while large pharmaceutical firms and established medical device companies are selectively partnering or acquiring capabilities to expand into regenerative cardiovascular solutions. Contract development and manufacturing organizations are emerging as critical enablers for teams that wish to scale production without the full capital burden of in-house infrastructure, and academic spinouts continue to supply early-stage innovation and domain expertise that feed the translational pipeline.

Strategic behaviors among these company types include forming co-development alliances to share clinical data and regulatory burden, licensing platform components to accelerate time-to-clinic, and structuring milestone-based partnerships to align incentives across development stages. Corporate venturing and targeted acquisitions are being used to internalize niche capabilities such as advanced biomaterials, scalable cell expansion, or proprietary bioprinting processes. Moreover, hospitals and research institutes are partnering with industry not only as trial sites but also as co-developers, providing physiological validation and access to patient cohorts. For investors and corporate strategists, the most compelling company profiles combine strong intellectual property, demonstrable manufacturing controls, and clear clinical endpoints that map to payer-relevant outcomes.

Actionable strategic priorities for industry leaders to align technology development, manufacturing, regulatory strategy, and partnership models for clinical success

Industry leaders should adopt a strategy that balances technological ambition with pragmatic operational execution to accelerate clinical translation and commercial adoption. First, prioritize platform robustness by investing in manufacturability early in development; building scalable, reproducible processes reduces late-stage risk and increases appeal to strategic partners and purchasers. Second, pursue modular product strategies that enable incremental clinical entry points while preserving the potential for expanded indications and platform evolution. This approach allows organizations to generate early clinical evidence in targeted use cases and iterate based on real-world performance.

Third, align regulatory and reimbursement engagement from program inception through clinical development. Proactive dialogue with regulators and payers helps define meaningful endpoints and evidence thresholds, smoothing pathways to market access. Fourth, design supply chain strategies that integrate local manufacturing options with diversified sourcing to mitigate policy-driven disruptions, control costs, and ensure continuity. Fifth, cultivate multidisciplinary partnerships across academia, hospitals, and specialized manufacturers to access complementary expertise and shared infrastructure, accelerating validation while optimizing capital deployment. Finally, embed post-market data strategies to capture longitudinal performance and safety signals, which strengthens clinical value propositions and supports broader adoption across care settings.

Robust mixed-methods research approach combining expert primary interviews, literature and patent analysis, regulatory review, and triangulated secondary data validation

The research methodology combined iterative primary research with comprehensive secondary analysis to construct a nuanced understanding of the cardiac tissue engineering landscape. Primary research consisted of in-depth interviews with a cross-section of stakeholders, including senior executives at biotechnology and device firms, manufacturing leaders, clinical investigators, and regulatory and reimbursement specialists. These conversations provided qualitative insights into strategic priorities, operational constraints, and evidence generation plans that shaped the analytical framework.

Secondary research involved a systematic review of peer-reviewed literature, clinical trial registries, patent filings, regulatory guidance documents, and publicly available corporate disclosures to validate technological claims and document translational milestones. Patent analytics were used to map innovation clusters and identify emerging platform capabilities, while clinical registry and trial data informed assessments of safety and feasibility trends. Finally, the methodology incorporated triangulation across data sources to reconcile divergent perspectives and ensure that conclusions reflect a balanced view of technical, commercial, and policy factors relevant to stakeholders making strategic decisions.

Synthesis of clinical, operational, and strategic imperatives that will determine which cardiac tissue engineering innovations achieve durable clinical and commercial impact

Cardiac tissue engineering stands at a pivotal inflection point where technological maturity, commercial intent, and regulatory pragmatism converge to enable meaningful clinical impact. The path forward will depend on developers' ability to translate platform innovations into manufacturable, safe, and efficacious therapies that meet the expectations of clinicians, regulators, and payers. Strategic emphasis on scalable manufacturing, diversified sourcing, and early regulatory engagement will be critical to converting scientific promise into durable clinical solutions.

Moreover, collaboration across industry, academia, and clinical partners will remain the most effective mechanism for managing development complexity and accelerating patient access. Organizations that balance scientific rigor with operational discipline and market-focused evidence generation will be best positioned to capture long-term value as the field progresses from niche feasibility to broader clinical integration. The next phase will reward those who can deliver repeatable clinical outcomes at scale while demonstrating value across diverse healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Tissue Engineering Market, by Product Type

• 8.1. Bioartificial Hearts
  • 8.1.1. Partial Hearts
  • 8.1.2. Whole Hearts
• 8.2. Cardiac Patches
  • 8.2.1. Decellularized Patches
  • 8.2.2. Electrospun Patches
• 8.3. Cardiac Scaffolds
  • 8.3.1. Biological Scaffolds
  • 8.3.2. Synthetic Scaffolds
• 8.4. Injectable Hydrogels
  • 8.4.1. Natural Hydrogels
  • 8.4.2. Synthetic Hydrogels

9. Cardiac Tissue Engineering Market, by Technology

• 9.1. 3D Bioprinting
  • 9.1.1. Extrusion Based
  • 9.1.2. Inkjet Based
  • 9.1.3. Laser Assisted
• 9.2. Decellularized Matrices
  • 9.2.1. Tissue Segment Decellularization
  • 9.2.2. Whole Organ Decellularization
• 9.3. Stem Cell Therapy
  • 9.3.1. Embryonic Stem Cells
  • 9.3.2. Induced Pluripotent Stem Cells
  • 9.3.3. Mesenchymal Stem Cells

10. Cardiac Tissue Engineering Market, by Cell Source

• 10.1. Allogeneic
  • 10.1.1. Donor Cardiomyocytes
  • 10.1.2. Donor Stromal Cells
• 10.2. Autologous
  • 10.2.1. Cardiomyocytes
  • 10.2.2. Stromal Cells
• 10.3. Xenogeneic
  • 10.3.1. Bovine Cells
  • 10.3.2. Porcine Cells

11. Cardiac Tissue Engineering Market, by Application

• 11.1. Heart Valve Regeneration
  • 11.1.1. Biological Valve Regeneration
  • 11.1.2. Mechanical Valve Replacement
• 11.2. Myocardial Repair
  • 11.2.1. Congenital Defect Repair
  • 11.2.2. Post Infarction Repair
• 11.3. Vascular Grafting
  • 11.3.1. Coronary Artery Bypass
  • 11.3.2. Peripheral Vascular Repair

12. Cardiac Tissue Engineering Market, by End User

• 12.1. Biotechnology Companies
• 12.2. Hospitals
• 12.3. Pharmaceutical Companies
• 12.4. Research Institutes

13. Cardiac Tissue Engineering Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Cardiac Tissue Engineering Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Cardiac Tissue Engineering Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Cardiac Tissue Engineering Market

17. China Cardiac Tissue Engineering Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. Artivion, Inc.
• 18.6. Auto Tissue Berlin GmbH
• 18.7. Avery Therapeutics, Inc.
• 18.8. Baxter Internatioal Inc.
• 18.9. BICO Group AB
• 18.10. Boston Scientific Corporation
• 18.11. BPS Bioscience, Inc.
• 18.12. Elutia Inc.
• 18.13. Fujifilm Holdings Corporation
• 18.14. Matricelf, Inc.
• 18.15. Medtronic Plc
• 18.16. Merck KGaA
• 18.17. Meril Lifesciences Pvt. Ltd.
• 18.18. Ncardia B.V.
• 18.19. Organovo Holdings, Inc.
• 18.20. PromoCell GmbH
• 18.21. Teijin Limited
• 18.22. Terumo Corporation
• 18.23. Vascudyne, Inc.
• 18.24. Viscofan DE GmbH

LIST OF FIGURES

• FIGURE 1. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL CARDIAC TISSUE ENGINEERING MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. UNITED STATES CARDIAC TISSUE ENGINEERING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 13. CHINA CARDIAC TISSUE ENGINEERING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PARTIAL HEARTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PARTIAL HEARTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PARTIAL HEARTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY WHOLE HEARTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY WHOLE HEARTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY WHOLE HEARTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED PATCHES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED PATCHES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ELECTROSPUN PATCHES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ELECTROSPUN PATCHES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ELECTROSPUN PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOLOGICAL SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOLOGICAL SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOLOGICAL SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY NATURAL HYDROGELS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY NATURAL HYDROGELS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY NATURAL HYDROGELS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY SYNTHETIC HYDROGELS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY SYNTHETIC HYDROGELS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY SYNTHETIC HYDROGELS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY EXTRUSION BASED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY EXTRUSION BASED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY EXTRUSION BASED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INKJET BASED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INKJET BASED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INKJET BASED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY LASER ASSISTED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY LASER ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY LASER ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TISSUE SEGMENT DECELLULARIZATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TISSUE SEGMENT DECELLULARIZATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TISSUE SEGMENT DECELLULARIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY WHOLE ORGAN DECELLULARIZATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY WHOLE ORGAN DECELLULARIZATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY WHOLE ORGAN DECELLULARIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY EMBRYONIC STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY EMBRYONIC STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 83. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 84. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
• TABLE 85. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DONOR CARDIOMYOCYTES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 86. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DONOR CARDIOMYOCYTES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 87. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DONOR CARDIOMYOCYTES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 88. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DONOR STROMAL CELLS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 89. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DONOR STROMAL CELLS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 90. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DONOR STROMAL CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 91. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 92. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 93. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 94. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
• TABLE 95. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIOMYOCYTES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 96. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIOMYOCYTES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 97. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIOMYOCYTES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 98. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STROMAL CELLS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 99. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STROMAL CELLS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 100. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STROMAL CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 101. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 102. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 103. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 104. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
• TABLE 105. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BOVINE CELLS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 106. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BOVINE CELLS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 107. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BOVINE CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 108. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PORCINE CELLS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 109. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PORCINE CELLS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 110. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PORCINE CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 111. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 112. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 113. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 114. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 115. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2032 (USD MILLION)
• TABLE 116. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOLOGICAL VALVE REGENERATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 117. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOLOGICAL VALVE REGENERATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 118. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOLOGICAL VALVE REGENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 119. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MECHANICAL VALVE REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 120. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MECHANICAL VALVE REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 121. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MECHANICAL VALVE REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 122. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 123. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 124. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 125. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2032 (USD MILLION)
• TABLE 126. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CONGENITAL DEFECT REPAIR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 127. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CONGENITAL DEFECT REPAIR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 128. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CONGENITAL DEFECT REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 129. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY POST INFARCTION REPAIR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 130. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY POST INFARCTION REPAIR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 131. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY POST INFARCTION REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 132. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 133. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 134. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 135. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2032 (USD MILLION)
• TABLE 136. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CORONARY ARTERY BYPASS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 137. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CORONARY ARTERY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 138. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CORONARY ARTERY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 139. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PERIPHERAL VASCULAR REPAIR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 140. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PERIPHERAL VASCULAR REPAIR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 141. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PERIPHERAL VASCULAR REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 142. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 143. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 144. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 145. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 146. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 147. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 148. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 149. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 150. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 151. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 152. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 153. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 154. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 155. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 156. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 157. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 158. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2032 (USD MILLION)
• TABLE 159. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2032 (USD MILLION)
• TABLE 160. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2032 (USD MILLION)
• TABLE 161. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2032 (USD MILLION)
• TABLE 162. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 163. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
• TABLE 164. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2032 (USD MILLION)
• TABLE 165. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
• TABLE 166. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
• TABLE 167. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
• TABLE 168. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
• TABLE 169. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
• TABLE 170. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 171. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2032 (USD MILLION)
• TABLE 172. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2032 (USD MILLION)
• TABLE 173. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2032 (USD MILLION)
• TABLE 174. AMERICAS CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 176. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2032 (USD MILLION)
• TABLE 178. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2032 (USD MILLION)
• TABLE 179. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2032 (USD MILLION)
• TABLE 180. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2032 (USD MILLION)
• TABLE 181. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 182. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
• TABLE 183. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2032 (USD MILLION)
• TABLE 184. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
• TABLE 185. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
• TABLE 186. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
• TABLE 187. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
• TABLE 188. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
• TABLE 189. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 190. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2032 (USD MILLION)
• TABLE 191. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2032 (USD MILLION)
• TABLE 192. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2032 (USD MILLION)
• TABLE 193. NORTH AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 194. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 196. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2032 (USD MILLION)
• TABLE 197. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2032 (USD MILLION)
• TABLE 198. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2032 (USD MILLION)
• TABLE 199. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2032 (USD MILLION)
• TABLE 200. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 201. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
• TABLE 202. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2032 (USD MILLION)
• TABLE 203. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
• TABLE 204. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
• TABLE 205. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
• TABLE 206. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
• TABLE 207. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
• TABLE 208. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 209. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2032 (USD MILLION)
• TABLE 210. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2032 (USD MILLION)
• TABLE 211. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2032 (USD MILLION)
• TABLE 212. LATIN AMERICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2032 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2032 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2032 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2032 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2032 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
• TABLE 227. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 228. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2032 (USD MILLION)
• TABLE 229. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2032 (USD MILLION)
• TABLE 230. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2032 (USD MILLION)
• TABLE 231. EUROPE, MIDDLE EAST & AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 232. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 233. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 234. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2032 (USD MILLION)
• TABLE 235. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2032 (USD MILLION)
• TABLE 236. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2032 (USD MILLION)
• TABLE 237. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2032 (USD MILLION)
• TABLE 238. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 239. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
• TABLE 240. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2032 (USD MILLION)
• TABLE 241. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
• TABLE 242. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
• TABLE 243. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
• TABLE 244. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
• TABLE 245. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
• TABLE 246. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 247. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2032 (USD MILLION)
• TABLE 248. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2032 (USD MILLION)
• TABLE 249. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2032 (USD MILLION)
• TABLE 250. EUROPE CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 251. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 252. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 253. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2032 (USD MILLION)
• TABLE 254. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2032 (USD MILLION)
• TABLE 255. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2032 (USD MILLION)
• TABLE 256. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2032 (USD MILLION)
• TABLE 257. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 258. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
• TABLE 259. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2032 (USD MILLION)
• TABLE 260. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
• TABLE 261. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
• TABLE 262. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
• TABLE 263. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
• TABLE 264. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
• TABLE 265. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 266. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2032 (USD MILLION)
• TABLE 267. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2032 (USD MILLION)
• TABLE 268. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2032 (USD MILLION)
• TABLE 269. MIDDLE EAST CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 270. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 271. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 272. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2032 (USD MILLION)
• TABLE 273. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2032 (USD MILLION)
• TABLE 274. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2032 (USD MILLION)
• TABLE 275. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2032 (USD MILLION)
• TABLE 276. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 277. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
• TABLE 278. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY DECELLULARIZED MATRICES, 2018-2032 (USD MILLION)
• TABLE 279. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY STEM CELL THERAPY, 2018-2032 (USD MILLION)
• TABLE 280. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
• TABLE 281. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
• TABLE 282. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
• TABLE 283. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
• TABLE 284. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 285. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY HEART VALVE REGENERATION, 2018-2032 (USD MILLION)
• TABLE 286. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY MYOCARDIAL REPAIR, 2018-2032 (USD MILLION)
• TABLE 287. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY VASCULAR GRAFTING, 2018-2032 (USD MILLION)
• TABLE 288. AFRICA CARDIAC TISSUE ENGINEERING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 289. ASIA-PACIFIC CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 290. ASIA-PACIFIC CARDIAC TISSUE ENGINEERING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 291. ASIA-PACIFIC CARDIAC TISSUE ENGINEERING MARKET SIZE, BY BIOARTIFICIAL HEARTS, 2018-2032 (USD MILLION)
• TABLE 292. ASIA-PACIFIC CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC PATCHES, 2018-2032 (USD MILLION)
• TABLE 293. ASIA-PACIFIC CARDIAC TISSUE ENGINEERING MARKET SIZE, BY CARDIAC SCAFFOLDS, 2018-2032 (USD MILLION)
• TABLE 294. ASIA-PACIFIC CARDIAC TISSUE ENGINEERING MARKET SIZE, BY INJECTABLE HYDROGELS, 2018-2032 (USD MILLION)
• TABLE 295. ASIA-PACIFIC CARDIAC TISSUE ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 296. ASIA-PACIFIC CARDIAC TISSUE E